| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanotubes, Carbon | 10 | 2017 | 23 | 2.610 |
Why?
|
| Silver | 4 | 2021 | 8 | 2.420 |
Why?
|
| Metal Nanoparticles | 4 | 2021 | 17 | 2.390 |
Why?
|
| Breast Neoplasms | 8 | 2021 | 754 | 1.500 |
Why?
|
| Hyperthermia, Induced | 6 | 2021 | 241 | 1.100 |
Why?
|
| Antineoplastic Agents | 5 | 2021 | 599 | 1.000 |
Why?
|
| Exosomes | 7 | 2021 | 44 | 0.990 |
Why?
|
| Cell Survival | 8 | 2021 | 280 | 0.960 |
Why?
|
| Cell Line, Tumor | 17 | 2021 | 726 | 0.860 |
Why?
|
| Genetic Vectors | 11 | 2009 | 120 | 0.750 |
Why?
|
| Adenoviridae | 9 | 2009 | 68 | 0.750 |
Why?
|
| Radiation, Ionizing | 1 | 2021 | 23 | 0.680 |
Why?
|
| Nanoparticles | 5 | 2021 | 56 | 0.680 |
Why?
|
| Phototherapy | 3 | 2016 | 51 | 0.650 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2021 | 15 | 0.640 |
Why?
|
| Cell Culture Techniques | 2 | 2018 | 172 | 0.640 |
Why?
|
| Acridines | 2 | 2017 | 19 | 0.630 |
Why?
|
| Drug Delivery Systems | 3 | 2016 | 105 | 0.630 |
Why?
|
| Platinum | 2 | 2017 | 21 | 0.630 |
Why?
|
| Gene Transfer Techniques | 8 | 2018 | 65 | 0.580 |
Why?
|
| Molecular Imaging | 2 | 2019 | 20 | 0.580 |
Why?
|
| Carbocyanines | 1 | 2018 | 3 | 0.560 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2015 | 27 | 0.550 |
Why?
|
| Fluorescent Dyes | 1 | 2018 | 47 | 0.540 |
Why?
|
| Animals | 29 | 2021 | 7569 | 0.510 |
Why?
|
| MicroRNAs | 4 | 2021 | 188 | 0.510 |
Why?
|
| bcl-X Protein | 1 | 2016 | 5 | 0.500 |
Why?
|
| Prostatic Neoplasms | 5 | 2019 | 476 | 0.500 |
Why?
|
| Alternative Splicing | 1 | 2016 | 32 | 0.500 |
Why?
|
| Carbohydrates | 1 | 2015 | 8 | 0.470 |
Why?
|
| Endothelial Cells | 1 | 2017 | 197 | 0.470 |
Why?
|
| Mice | 25 | 2021 | 2511 | 0.450 |
Why?
|
| Neoplasms | 4 | 2013 | 761 | 0.410 |
Why?
|
| Humans | 34 | 2021 | 32798 | 0.380 |
Why?
|
| Nanomedicine | 2 | 2009 | 16 | 0.370 |
Why?
|
| Lipid Bilayers | 2 | 2008 | 5 | 0.360 |
Why?
|
| Female | 19 | 2021 | 20261 | 0.340 |
Why?
|
| Graft Rejection | 1 | 2011 | 241 | 0.310 |
Why?
|
| Tissue Donors | 1 | 2011 | 207 | 0.310 |
Why?
|
| Enterovirus | 3 | 2008 | 4 | 0.310 |
Why?
|
| Bone Neoplasms | 2 | 2021 | 116 | 0.290 |
Why?
|
| Infrared Rays | 3 | 2021 | 20 | 0.290 |
Why?
|
| Virus Assembly | 1 | 2008 | 4 | 0.290 |
Why?
|
| Viral Envelope Proteins | 1 | 2008 | 10 | 0.290 |
Why?
|
| Nanotechnology | 1 | 2008 | 18 | 0.280 |
Why?
|
| Plasmids | 2 | 2005 | 45 | 0.280 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2008 | 19 | 0.280 |
Why?
|
| Apoptosis | 2 | 2021 | 362 | 0.260 |
Why?
|
| DNA | 2 | 2005 | 218 | 0.260 |
Why?
|
| Kidney Transplantation | 1 | 2011 | 512 | 0.250 |
Why?
|
| Cations | 2 | 2021 | 10 | 0.240 |
Why?
|
| Cell Death | 3 | 2021 | 71 | 0.230 |
Why?
|
| Hypertension | 1 | 2011 | 976 | 0.210 |
Why?
|
| Cell Proliferation | 5 | 2018 | 602 | 0.210 |
Why?
|
| Tissue Distribution | 3 | 2016 | 58 | 0.210 |
Why?
|
| Promoter Regions, Genetic | 4 | 2016 | 208 | 0.190 |
Why?
|
| Up-Regulation | 3 | 2018 | 191 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 6 | 2013 | 169 | 0.180 |
Why?
|
| Hydrogen Peroxide | 1 | 2021 | 84 | 0.170 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 563 | 0.160 |
Why?
|
| Qa-SNARE Proteins | 1 | 2019 | 6 | 0.160 |
Why?
|
| Genetic Engineering | 3 | 2009 | 18 | 0.160 |
Why?
|
| Phenylthiohydantoin | 1 | 2019 | 8 | 0.160 |
Why?
|
| Indicators and Reagents | 2 | 2018 | 14 | 0.160 |
Why?
|
| Protein Binding | 2 | 2017 | 200 | 0.150 |
Why?
|
| Phenotype | 2 | 2019 | 638 | 0.150 |
Why?
|
| Proteome | 1 | 2019 | 40 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 264 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 222 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 2 | 2018 | 160 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 19 | 0.140 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 34 | 0.140 |
Why?
|
| Cytological Techniques | 1 | 2018 | 17 | 0.140 |
Why?
|
| Molecular Probes | 1 | 2018 | 16 | 0.140 |
Why?
|
| Staining and Labeling | 1 | 2018 | 57 | 0.140 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2018 | 17 | 0.140 |
Why?
|
| Proteomics | 1 | 2019 | 97 | 0.140 |
Why?
|
| Mice, Nude | 5 | 2021 | 290 | 0.140 |
Why?
|
| Adaptor Protein Complex 2 | 1 | 2017 | 2 | 0.140 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 79 | 0.140 |
Why?
|
| Microglia | 1 | 2018 | 68 | 0.140 |
Why?
|
| Cells, Cultured | 4 | 2017 | 820 | 0.140 |
Why?
|
| Mitochondrial Proteins | 1 | 2018 | 71 | 0.130 |
Why?
|
| Placenta | 1 | 2018 | 75 | 0.130 |
Why?
|
| Plastics | 1 | 2017 | 1 | 0.130 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 69 | 0.130 |
Why?
|
| Silicon Dioxide | 1 | 2017 | 10 | 0.130 |
Why?
|
| Coordination Complexes | 1 | 2017 | 7 | 0.130 |
Why?
|
| Basement Membrane | 1 | 2017 | 8 | 0.130 |
Why?
|
| Drug Carriers | 1 | 2017 | 24 | 0.130 |
Why?
|
| Molecular Probe Techniques | 1 | 2016 | 4 | 0.130 |
Why?
|
| Microvessels | 1 | 2017 | 28 | 0.130 |
Why?
|
| RNA, Messenger | 3 | 2016 | 498 | 0.130 |
Why?
|
| Benzamides | 1 | 2016 | 54 | 0.130 |
Why?
|
| RNA Precursors | 1 | 2016 | 2 | 0.130 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2016 | 2 | 0.130 |
Why?
|
| Gene Knockout Techniques | 1 | 2016 | 15 | 0.130 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 111 | 0.120 |
Why?
|
| Macrophages, Alveolar | 4 | 2000 | 11 | 0.120 |
Why?
|
| Ethylenediamines | 1 | 2016 | 6 | 0.120 |
Why?
|
| Protein Isoforms | 1 | 2016 | 59 | 0.120 |
Why?
|
| Chelating Agents | 1 | 2016 | 17 | 0.120 |
Why?
|
| Mitochondria | 1 | 2018 | 206 | 0.120 |
Why?
|
| Zinc | 1 | 2016 | 31 | 0.120 |
Why?
|
| Base Sequence | 1 | 2016 | 247 | 0.120 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 167 | 0.120 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 134 | 0.120 |
Why?
|
| Stem Cells | 1 | 2018 | 314 | 0.120 |
Why?
|
| Melanoma | 1 | 2016 | 165 | 0.110 |
Why?
|
| Estrogens | 1 | 2016 | 169 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 9 | 2018 | 789 | 0.110 |
Why?
|
| African Americans | 2 | 2019 | 1424 | 0.110 |
Why?
|
| Microscopy, Electron, Transmission | 3 | 2017 | 37 | 0.110 |
Why?
|
| Brain | 2 | 2018 | 946 | 0.100 |
Why?
|
| Electroporation | 1 | 2013 | 14 | 0.100 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2012 | 3 | 0.100 |
Why?
|
| Hot Temperature | 1 | 2012 | 78 | 0.090 |
Why?
|
| Gene Expression | 5 | 2000 | 334 | 0.090 |
Why?
|
| Male | 8 | 2019 | 19641 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 98 | 0.090 |
Why?
|
| Time Factors | 2 | 2013 | 2183 | 0.090 |
Why?
|
| Cadaver | 1 | 2011 | 165 | 0.080 |
Why?
|
| Creatinine | 1 | 2011 | 198 | 0.080 |
Why?
|
| Kidney Neoplasms | 2 | 2011 | 205 | 0.080 |
Why?
|
| Dendritic Cells | 2 | 2001 | 59 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 384 | 0.080 |
Why?
|
| DNA, Complementary | 6 | 2000 | 30 | 0.080 |
Why?
|
| Iron | 1 | 2011 | 116 | 0.080 |
Why?
|
| Electrochemotherapy | 1 | 2010 | 3 | 0.080 |
Why?
|
| Needles | 1 | 2010 | 31 | 0.080 |
Why?
|
| Iron Chelating Agents | 1 | 2009 | 7 | 0.080 |
Why?
|
| Capsid | 1 | 2009 | 8 | 0.080 |
Why?
|
| Capsid Proteins | 1 | 2009 | 9 | 0.080 |
Why?
|
| Cyclic AMP | 3 | 1998 | 45 | 0.070 |
Why?
|
| Survival Rate | 1 | 2011 | 894 | 0.070 |
Why?
|
| Viremia | 1 | 2008 | 5 | 0.070 |
Why?
|
| Microscopy, Atomic Force | 1 | 2008 | 5 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2009 | 186 | 0.070 |
Why?
|
| Quaternary Ammonium Compounds | 2 | 2005 | 7 | 0.070 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 72 | 0.070 |
Why?
|
| Biomedical Engineering | 1 | 2008 | 26 | 0.070 |
Why?
|
| Thrombopoietin | 2 | 1998 | 4 | 0.070 |
Why?
|
| Injections, Intravenous | 2 | 2006 | 79 | 0.070 |
Why?
|
| Materials Testing | 1 | 2008 | 92 | 0.070 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 1997 | 12 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2011 | 1844 | 0.060 |
Why?
|
| Prostate | 2 | 2018 | 69 | 0.060 |
Why?
|
| Indium Radioisotopes | 1 | 2006 | 1 | 0.060 |
Why?
|
| Pentetic Acid | 1 | 2006 | 3 | 0.060 |
Why?
|
| Half-Life | 1 | 2006 | 22 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2006 | 49 | 0.060 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2001 | 35 | 0.060 |
Why?
|
| Surface Plasmon Resonance | 1 | 2005 | 7 | 0.060 |
Why?
|
| Lysine | 1 | 2005 | 23 | 0.060 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2005 | 94 | 0.060 |
Why?
|
| Platelet Count | 2 | 2011 | 23 | 0.060 |
Why?
|
| Pseudomonas Infections | 2 | 2001 | 14 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2018 | 686 | 0.050 |
Why?
|
| European Continental Ancestry Group | 2 | 2019 | 1163 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2001 | 55 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2021 | 453 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2011 | 3438 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2011 | 3701 | 0.050 |
Why?
|
| Receptors, Virus | 2 | 2000 | 15 | 0.050 |
Why?
|
| Cell Division | 2 | 2001 | 94 | 0.050 |
Why?
|
| Particle Size | 2 | 2017 | 47 | 0.050 |
Why?
|
| Virus Replication | 2 | 1999 | 42 | 0.040 |
Why?
|
| Oxidative Stress | 2 | 2016 | 239 | 0.040 |
Why?
|
| Osteoclasts | 1 | 2021 | 24 | 0.040 |
Why?
|
| Bacterial Vaccines | 1 | 2001 | 8 | 0.040 |
Why?
|
| Genes, Reporter | 2 | 1998 | 39 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2021 | 106 | 0.040 |
Why?
|
| CD40 Ligand | 1 | 2000 | 12 | 0.040 |
Why?
|
| Temperature | 2 | 2012 | 51 | 0.040 |
Why?
|
| Lung | 2 | 1999 | 265 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 220 | 0.040 |
Why?
|
| Lymphokines | 1 | 2000 | 11 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2000 | 12 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 2000 | 13 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2000 | 18 | 0.040 |
Why?
|
| Vaccination | 1 | 2001 | 146 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2000 | 88 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 1999 | 7 | 0.040 |
Why?
|
| Receptors, HIV | 1 | 1999 | 1 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 1999 | 11 | 0.040 |
Why?
|
| HIV-1 | 1 | 1999 | 45 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2019 | 42 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 107 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1999 | 27 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 60 | 0.040 |
Why?
|
| Transfection | 1 | 1999 | 184 | 0.040 |
Why?
|
| Genome, Viral | 1 | 1998 | 10 | 0.040 |
Why?
|
| Cholesterol | 1 | 2000 | 253 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 102 | 0.040 |
Why?
|
| rab5 GTP-Binding Proteins | 1 | 2018 | 3 | 0.040 |
Why?
|
| Benzylidene Compounds | 1 | 2018 | 6 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2018 | 18 | 0.040 |
Why?
|
| Adult | 1 | 2011 | 9560 | 0.040 |
Why?
|
| Chimera | 1 | 1998 | 10 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 134 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 245 | 0.030 |
Why?
|
| Sulfenic Acids | 1 | 2018 | 54 | 0.030 |
Why?
|
| Cystic Fibrosis | 1 | 1997 | 23 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 193 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 497 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2018 | 267 | 0.030 |
Why?
|
| Macrophages | 1 | 2019 | 194 | 0.030 |
Why?
|
| Surface Properties | 1 | 2017 | 36 | 0.030 |
Why?
|
| Porosity | 1 | 2017 | 39 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2017 | 69 | 0.030 |
Why?
|
| Phospholipids | 1 | 2017 | 29 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2016 | 17 | 0.030 |
Why?
|
| Isotope Labeling | 1 | 2016 | 16 | 0.030 |
Why?
|
| Middle Aged | 1 | 2011 | 12125 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 64 | 0.030 |
Why?
|
| Calcium | 1 | 2019 | 323 | 0.030 |
Why?
|
| Lipids | 1 | 2018 | 229 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 80 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 1996 | 18 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 178 | 0.030 |
Why?
|
| Aptamers, Nucleotide | 1 | 2016 | 10 | 0.030 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2016 | 8 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 92 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2016 | 24 | 0.030 |
Why?
|
| Liposomes | 1 | 2016 | 30 | 0.030 |
Why?
|
| Neurons | 1 | 2019 | 416 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 1997 | 475 | 0.030 |
Why?
|
| Pregnancy | 1 | 2018 | 981 | 0.030 |
Why?
|
| Liver | 1 | 1998 | 492 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1544 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 60 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 51 | 0.020 |
Why?
|
| Cell Line | 3 | 1999 | 433 | 0.020 |
Why?
|
| Thermography | 1 | 2012 | 3 | 0.020 |
Why?
|
| Absorption | 1 | 2012 | 15 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2012 | 59 | 0.020 |
Why?
|
| Laser Therapy | 1 | 2012 | 56 | 0.020 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2012 | 8 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2012 | 18 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 51 | 0.020 |
Why?
|
| von Willebrand Factor | 1 | 2011 | 14 | 0.020 |
Why?
|
| Platelet Activation | 1 | 2011 | 14 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2011 | 18 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 152 | 0.020 |
Why?
|
| Thrombosis | 1 | 2011 | 81 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 486 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 138 | 0.020 |
Why?
|
| Electrodes | 1 | 2010 | 18 | 0.020 |
Why?
|
| Siderophores | 1 | 2009 | 1 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 115 | 0.020 |
Why?
|
| Iron Overload | 1 | 2009 | 38 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 33 | 0.020 |
Why?
|
| United States | 1 | 2018 | 4108 | 0.020 |
Why?
|
| Luminescent Proteins | 2 | 1999 | 26 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 1999 | 72 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2009 | 114 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 1999 | 247 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 1307 | 0.010 |
Why?
|
| Ethylene Glycols | 1 | 2004 | 6 | 0.010 |
Why?
|
| Carbon | 1 | 2004 | 11 | 0.010 |
Why?
|
| CHO Cells | 1 | 2004 | 24 | 0.010 |
Why?
|
| Pyrrolidines | 1 | 2004 | 12 | 0.010 |
Why?
|
| Cricetinae | 1 | 2004 | 39 | 0.010 |
Why?
|
| Rats | 2 | 1999 | 1606 | 0.010 |
Why?
|
| Hela Cells | 1 | 2004 | 80 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2004 | 96 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 2001 | 31 | 0.010 |
Why?
|
| Immunization | 1 | 2000 | 33 | 0.010 |
Why?
|
| Evans Blue | 1 | 2000 | 1 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2000 | 13 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 2000 | 19 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 2000 | 18 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2000 | 80 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2000 | 10 | 0.010 |
Why?
|
| Transgenes | 1 | 2000 | 49 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2000 | 54 | 0.010 |
Why?
|
| Water | 1 | 2000 | 61 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2000 | 30 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2000 | 11 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2000 | 77 | 0.010 |
Why?
|
| Skin Physiological Phenomena | 1 | 2000 | 7 | 0.010 |
Why?
|
| Opsonin Proteins | 1 | 1999 | 5 | 0.010 |
Why?
|
| Phagocytes | 1 | 1999 | 4 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2000 | 117 | 0.010 |
Why?
|
| Phagocytosis | 1 | 1999 | 17 | 0.010 |
Why?
|
| Receptors, CCR3 | 1 | 1999 | 2 | 0.010 |
Why?
|
| Chemokine CCL4 | 1 | 1999 | 4 | 0.010 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 1999 | 3 | 0.010 |
Why?
|
| Receptors, CCR5 | 1 | 1999 | 3 | 0.010 |
Why?
|
| Chemokine CCL3 | 1 | 1999 | 5 | 0.010 |
Why?
|
| Chemokine CCL5 | 1 | 1999 | 7 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 1999 | 11 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 1999 | 11 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2000 | 65 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1999 | 48 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2000 | 114 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1999 | 20 | 0.010 |
Why?
|
| Cytokines | 1 | 2000 | 247 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1999 | 59 | 0.010 |
Why?
|
| Sheep | 1 | 1999 | 233 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1999 | 91 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1999 | 59 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 1999 | 129 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1998 | 18 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1999 | 186 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 1998 | 42 | 0.010 |
Why?
|
| Species Specificity | 1 | 1998 | 88 | 0.010 |
Why?
|
| Avian Sarcoma Viruses | 1 | 1998 | 1 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 7 | 0.010 |
Why?
|
| Luciferases | 1 | 1998 | 31 | 0.010 |
Why?
|
| Anions | 1 | 1997 | 2 | 0.010 |
Why?
|
| Chlorides | 1 | 1997 | 13 | 0.010 |
Why?
|
| Megakaryocytes | 1 | 1997 | 4 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1997 | 15 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1997 | 31 | 0.010 |
Why?
|
| Spleen | 1 | 1997 | 85 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1997 | 100 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 1997 | 123 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1998 | 754 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1996 | 157 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1996 | 428 | 0.010 |
Why?
|